Compare AbbVie Inc (ABBV) vs Harmony Gold Mining Co. (HMY) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Harmony Gold Mining (HMY) trades at $15.385, down 4.38% amid broader gold sector weakness. The stock shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, representing a 13.99% margin. Technical indicators signal bearish momentum with RSI at oversold levels. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while analysts maintain a cautious stance with 70% hold ratings.

HMY presents value with attractive valuation ratios (P/E 10.42, EV/EBITDA 5.36) and robust profitability (ROE 32.32%). However, Fed rate hike concerns and gold price volatility pose near-term headwinds. The company's transition to gold-copper hybrid operations by 2028 offers long-term growth potential, though execution risks and commodity price exposure remain key considerations for investors.